October 2019 – Proactive Investors: ‘All systems go’ for ReNeuron’s retinitis pigmentosa programme as it looks to follow-up studies
Proactive Investors: ReNeuron makes key business development hire as it looks to build on licensing deals
Proactive Investors: “ReNeuron ‘very encouraged’ by positive retinitis pigmentosa study results”
Proactive Investors : “ReNeuron Group agrees £80mln cell therapy licensing deal for China”
Proactive Investors ‘ReNeuron provides encouraging update to phase II eye disease trial’
Proactive Investors ‘ReNeuron Group’s phase IIb stroke trial kicks off with first patient treated’
Proactive Investors: ReNeuron seeing increased interest across its assets from potential licensee partners
Proactive Investors : “ReNeuron signs exosome collaboration deal with US biopharma”
OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Proactive Investors ‘ReNeuron focus on new clinical trials’